Literature DB >> 1618894

High-dose folinic acid and 5-fluorouracil plus cisplatin on a weekly schedule in the treatment of advanced cancer of the head and neck.

V Gebbia1, A Russo, N Gebbia, L Rausa, F Ingria, G Spatafora, G Zerillo, A Cimino, T Pastorello, P Ferrara.   

Abstract

A group of 60 patients with advanced head/neck cancer were treated with high-dose folinic acid (500 mg/m-2/week-1) plus 5-fluorouracil (400 mg/m-2/week-1 on day 1, and cisplatin (20 mg/m-2/week-1) 24 h after folinic acid infusion was completed. Out of 55 evaluable patients, 10 patients (18%) experienced a complete response with a mean duration of 11.4+ months, 25 patients had a partial response (45%) of 6.7+ months, 6 patients (11%) showed a stabilization of 4.8+ months, and 14 (25%) progressed. The overall response rate was 63.6% (95% confidence limits 56.5%-69.5%). Patients pretreated with radiotherapy had a 67% overall response rate, while those pretreated with chemotherapy showed a 54% overall response rate. All patients with cancer of the oropharynx had a major response, while patients with cancer of the oral cavity had the lowest response rate. The mean survival of patients who attained a complete response was 14.5+ months. Partial responders had a mean survival of 10.6+ months, while patients who progresses survived a mean of 3.6+ months. The treatment has been very well tolerated with few cases of grade 3 gastrointestinal toxicity. Grade 1-2 leukopenia was recorded in 64% of cases, grade 1-2 nausea/vomiting in 85%. In one case therapy was stopped because of persistent diarrhoea.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1618894     DOI: 10.1007/bf01629430

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  28 in total

Review 1.  Head and neck cancer: chemotherapy concepts.

Authors:  M Al-Sarraf
Journal:  Semin Oncol       Date:  1988-02       Impact factor: 4.929

2.  Biochemical factors affecting the tightness of 5-fluorodeoxyuridylate binding to human thymidylate synthetase.

Authors:  A Lockshin; P V Danenberg
Journal:  Biochem Pharmacol       Date:  1981-02-01       Impact factor: 5.858

3.  Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate.

Authors:  D V Santi; C S McHenry; H Sommer
Journal:  Biochemistry       Date:  1974-01-29       Impact factor: 3.162

4.  Structures of reversible and irreversible complexes of thymidylate synthetase and fluorinated pyrimidine nucleotides.

Authors:  P V Danenberg; R J Langenbach; C Heidelberger
Journal:  Biochemistry       Date:  1974-02-26       Impact factor: 3.162

5.  A prospective evaluation of 5-fluorouracil plus cisplatin in advanced squamous-cell cancer of the head and neck.

Authors:  K S Dasmahapatra; P Citrin; G J Hill; R Yee; M A Mohit-Tabatabai; B F Rush
Journal:  J Clin Oncol       Date:  1985-11       Impact factor: 44.544

6.  Four-day continuous infusion of cisplatin and 5-fluorouracil in head and neck cancer.

Authors:  A G Bernal; J J Cruz; P Sánchez; A Muñoz; A Nieto; E Fonseca; R Calle; J L Gómez
Journal:  Cancer       Date:  1989-05-15       Impact factor: 6.860

7.  Treatment of squamous-cell carcinoma of the head and neck with cisplatin and 5-fluorouracil.

Authors:  P C Amrein; S A Weitzman
Journal:  J Clin Oncol       Date:  1985-12       Impact factor: 44.544

8.  A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma.

Authors:  C Erlichman; S Fine; A Wong; T Elhakim
Journal:  J Clin Oncol       Date:  1988-03       Impact factor: 44.544

9.  Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells.

Authors:  K J Scanlon; E M Newman; Y Lu; D G Priest
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

10.  The role of drug sequence in therapeutic selectivity of the combination of 5-fluorouracil and cis-platin.

Authors:  S Palmeri; F Trave; O Russello; Y M Rustum
Journal:  Sel Cancer Ther       Date:  1989
View more
  2 in total

1.  Weekly 5-fluorouracil and folinic acid plus escalating doses of cisplatin with glutathione protection in patients with advanced head and neck cancer.

Authors:  V Gebbia; R Valenza; A Testa; G Zerillo; S Restivo; G Cupido; F Ingria; G Spadafora; C Barbaccia; G Cannata
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

2.  Chemotherapeutic treatment of recurrent and/or metastatic nasopharyngeal carcinoma: a retrospective analysis of 40 cases.

Authors:  V Gebbia; G Zerillo; G Restivo; R Speciale; G Cupido; P Lo Bue; F Ingria; S Gallina; G Spatafora; A Testa
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.